← Leaderboards
Xiaochao Ma
University Of Kansas Medical Center
$6,231,357
Attributed
$6,231,357
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $948.2K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,231,357 · 6
By mechanism
R01$5,220,910 · 3
R21$421,199 · 1
R56$377,513 · 1
P20$211,735 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Metabolism”
- David M Nathan · Massachusetts Institute Of Technology$157,845,616
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$141,260,706
- John M Lachin · George Washington University$139,991,329
- Randall J Bateman · Washington University$124,168,384
- Carol Nesel · Westat$116,355,411
Research focus
MetabolismSafetyMediatingMouse ModelHepatotoxicityLiverBasePathway InteractionsReceptor ActivationLiver InjuryPregnane X ReceptorEnzymesPharmaceutical PreparationsPreventNovel StrategiesPublic Health RelevanceGenetic EngineeringTranscription FactorLigandsRifampinAnalogLiver FailureMetabolomicsProtoporphyrin Ix
Grant awards (21)
The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy$340,040
R01 · FY2025 · DK · contact PI
The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy$326,710
R01 · FY2024 · DK · contact PI
The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy$340,600
R01 · FY2023 · DK · contact PI
The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy$340,014
R01 · FY2022 · DK · contact PI
Pharmacoenhancers for antiretroviral therapy: safety and future development$382,103
R01 · FY2021 · AI · contact PI
The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy$335,995
R01 · FY2021 · DK · contact PI
Preclinical screening and validation for PXR-mediated herb-drug interactions associated with anti-HIV therapy$230,094
R21 · FY2021 · AT · contact PI
Pharmacoenhancers for antiretroviral therapy: safety and future development$382,369
R01 · FY2020 · AI · contact PI
Preclinical screening and validation for PXR-mediated herb-drug interactions associated with anti-HIV therapy$191,105
R21 · FY2020 · AT · contact PI
Pharmacoenhancers for antiretroviral therapy: safety and future development$382,628
R01 · FY2019 · AI · contact PI
Pharmacoenhancers for antiretroviral therapy: safety and future development$382,683
R01 · FY2018 · AI · contact PI
Pharmacoenhancers for antiretroviral therapy: safety and future development$380,472
R01 · FY2017 · AI · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$328,470
R01 · FY2016 · DK · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$328,470
R01 · FY2015 · DK · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$327,186
R01 · FY2014 · DK · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$167,986
R01 · FY2013 · DK · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$146,759
R01 · FY2013 · DK · contact PI
Mechanisms of adverse effects of anti-tuberculosis drugs$328,425
R01 · FY2012 · DK · contact PI
Drug-induced liver injury associated with anti-retroviral therapy$194,195
R56 · FY2012 · AI · contact PI
Drug-induced liver injury associated with anti-retroviral therapy$183,318
R56 · FY2012 · AI · contact PI
THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURY$211,735
P20 · FY2011 · RR · contact PI